// Auto-generated - do not edit
export const substanceName = "Phenobarbital";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Phenobarbital.md","displayName":"DrugBank","size":26788},{"id":"isomerdesign","fileName":"ISOMERDESIGN - Phenobarbital.md","displayName":"Isomer Design","size":702},{"id":"protestkit","fileName":"PROTESTKIT - Phenobarbital.json","displayName":"Protest Kit","size":3419},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - Phenobarbital.md","displayName":"PsychonautWiki","size":24734},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Phenobarbital.md","displayName":"TripSit Factsheets","size":496},{"id":"wikipedia","fileName":"WIKIPEDIA - Phenobarbital.md","displayName":"Wikipedia","size":15471}];
export const contents: Record<string, string> = {
  "drugbank": `# Phenobarbital
*Source: https://go.drugbank.com/drugs/DB01174*

## Overview

### Description

This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.

### Background

A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

### Indication

For the treatment of all types of seizures except absence seizures.

### Pharmacodynamics

Phenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal).

### Mechanism of Action

Gamma-aminobutyric acid receptor subunit alpha-1
Potentiator

### Absorption

Absorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach.

### Metabolism

Hepatic (mostly via CYP2C19).
Hover over products below to view reaction partners
Phenobarbital
p-Hydroxyphenobarbital
Phenobarbital O-glucuronide
Phenobarbital O-sulfate

### Half-life

53 to 118 hours (mean 79 hours)

### Toxicity

CNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may wshow paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The metabolism of 1,2-Benzodiazepine can be increased when combined with Phenobarbital.
Abacavir
The metabolism of Abacavir can be increased when combined with Phenobarbital.
Abaloparatide
Phenobarbital may increase the hypotensive activities of Abaloparatide.
Abatacept
The metabolism of Phenobarbital can be increased when combined with Abatacept.
Abemaciclib
The metabolism of Abemaciclib can be increased when combined with Phenobarbital.

### Food Interactions

Administer vitamin supplements.
Avoid alcohol.
Limit caffeine intake.
Take on an empty stomach. Taking this medication on an empty stomach increases the speed of absorption.

## Chemical Information

**DrugBank ID:** DB01174

**Synonyms:** 5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione
5-Ethyl-5-phenylbarbituric acid
5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
5-Phenyl-5-ethylbarbituric acid
Fenobarbital
Phenobarbital
Phenobarbitol
Phenobarbitone
Phenobarbituric Acid
Phenyläthylbarbitursäure
Phenylethylbarbiturate
Phenylethylbarbituric Acid
Phenylethylbarbitursäure
Phenylethylmalonylurea

**Chemical Formula:** C
12
H
12
N
2
O
3

**SMILES:** CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1

**Weight:** Average: 232.2353
Monoisotopic: 232.08479226

**IUPAC Name:** 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
US11857683
No
2024-01-02
2042-04-07
US

### Indicated Conditions

9

### Phase 0

0

### Phase 1

3

### Phase 2

6

### Phase 3

11

### Phase 4

8

### Therapeutic Categories

Barbiturates

### Summary

Phenobarbital
is a long-lasting barbiturate and anticonvulsant used in the treatment of all types of seizures, except for absent seizures.

### Brand Names

Donnatal, Luminal, Phenobarb, Phenohytro, Sezaby

### Generic Name

Phenobarbital

### DrugBank Accession Number

DB01174

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Phenobarbital (DB01174)
×
Close

### External IDs

NSC-128143
NSC-9848

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Symptomatic treatment of
Alcohol withdrawal
••• •••••
Create Account
Treatment of
Anxiety
••••••••••••
Create Account
Treatment of
Febrile seizures
••••••••••••
Create Account
Prophylaxis of
Febrile seizures
••••••••••••
Create Account
Treatment of
Hyperbilirubinemia
••••••••••••
Create Account
Create Account

### Associated Therapies

Sedation

### Mechanism of action

Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.
Target
Actions
Organism
A
Gamma-aminobutyric acid receptor subunit alpha-1
potentiator
Humans
U
Neuronal acetylcholine receptor subunit alpha-4
antagonist
Humans
U
Neuronal acetylcholine receptor subunit alpha-7
antagonist
Humans
U
Glutamate receptor 2
antagonist
Humans
U
Glutamate receptor ionotropic, kainate 2
antagonist
Humans
U
NMDA receptor
antagonist
Humans
U
Nuclear receptor subfamily 1 group I member 2
activator
Humans

### Protein binding

20 to 45%

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Phenobarbital sodium
SW9M9BB5K3
57-30-7
WRLGYAWRGXKSKG-UHFFFAOYSA-M

### Product Images

Previous
Next

### International/Other Brands

Luminal

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Phenobarbital
Tablet
32.4 mg/1
Oral
E5 Pharma, Llc
2017-02-24
2025-11-09
US
Phenobarbital
Liquid
20 mg/5mL
Oral
bryant ranch prepack
2020-09-01
Not applicable
US
Phenobarbital
Tablet
16.2 mg/1
Oral
QUAGEN PHARMACEUTICALS LLC
2020-09-15
Not applicable
US
Phenobarbital
Tablet
100 mg/1
Oral
Genus Lifesciences Inc.
2025-03-01
Not applicable
US
Phenobarbital
Tablet
32.4 mg/1
Oral
Sterling-Knight Pharmaceuticals, LLC
2017-03-28
Not applicable
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Bellergal Spacetabs
Phenobarbital
(40.0 mg)
+
Belladonna
(0.2 mg)
+
Ergotamine tartrate
(0.6 mg)
Tablet, extended release
Oral
Paladin Pharma Inc.
1959-01-01
2018-06-05
Canada
Bellergal Tab
Phenobarbital
(20 mg / tab)
+
Belladonna
(.1 mg / tab)
+
Ergotamine tartrate
(.3 mg / tab)
Tablet
Oral
Sandoz S.P.A.
1951-12-31
1997-08-12
Canada
Diclophen
Phenobarbital
(15 mg)
+
Dicyclomine hydrochloride
(10 mg)
Capsule
Oral
Pro Doc Limitee
1970-12-31
2009-07-23
Canada
Dilantin W Phenobarbital 15mg
Phenobarbital
(15 mg / cap)
+
Phenytoin sodium
(100 mg / cap)
Capsule
Oral
Parke Davis Division, Warner Lambert Canada Inc.
1951-12-31
1999-04-08
Canada
Dilantin W Phenobarbital 30mg Cap
Phenobarbital
(30 mg / cap)
+
Phenytoin sodium
(100 mg / cap)
Capsule
Oral
Parke Davis Division, Warner Lambert Canada Inc.
1969-12-31
1997-08-25
Canada

### Unapproved/Other Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
B-Donna
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
Winder Laboratories, LLC
2015-12-30
2016-03-03
US
Belladonna Alkaloids with Phenobarbital
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
Hikma Pharmaceuticals USA Inc.
1966-01-01
2019-07-31
US
Belladonna Alkaloids with Phenobarbital
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
bryant ranch prepack
1966-01-01
2015-05-01
US
Belladonna Alkaloids with Phenobartbital
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
Liberty Pharmaceuticals, Inc.
2000-12-01
Not applicable
US
Belladonna Alkaloids with Phenobartbital
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
Physicians Total Care, Inc.
2004-08-31
2013-01-15
US

### ATC Codes

N05CB01 — Combinations of barbiturates
N05CB — Barbiturates, combinations
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM
N03AA02 — Phenobarbital
N03AA — Barbiturates and derivatives
N03A — ANTIEPILEPTICS
N03 — ANTIEPILEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Anticholinergic Agents
Anticonvulsants
Barbiturates
Barbiturates and Derivatives
BSEP/ABCB11 inducers
Central Nervous System Agents
Central Nervous System Depressants
Chemically-Induced Disorders
Cytochrome P-450 CYP1A2 Inducers
Cytochrome P-450 CYP1A2 Inducers (strength unknown)
Cytochrome P-450 CYP2A6 Inducers
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 CYP2B6 Inducers (strong)
Cytochrome P-450 CYP2C18 Substrates
Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C19 Inducers (strength unknown)
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C8 Inducers (strength unknown)
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP2C9 Inducers (strength unknown)
Cytochrome P-450 CYP2C9 Substrates
Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 CYP2E1 Inducers
Cytochrome P-450 CYP2E1 Inducers (strength unknown)
Cytochrome P-450 CYP2E1 Inducers (weak)
Cytochrome P-450 CYP2E1 Substrates
Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 CYP3A Inducers (strong)
Cytochrome P-450 CYP3A4 Inducers
Cytochrome P-450 CYP3A4 Inducers (strong)
Cytochrome P-450 CYP3A5 Inducers
Cytochrome P-450 CYP3A5 Inducers (strong)
Cytochrome P-450 CYP3A7 Inducers
Cytochrome P-450 CYP3A7 Inducers (strength unknown)
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 Substrates
Enzyme Inducing Antiepileptic Drugs
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
GABA Agents
GABA Modulators
Hypnotics and Sedatives
Methemoglobinemia Associated Agents
Narrow Therapeutic Index Drugs
Nervous System
Neurotransmitter Agents
Nicotinic Antagonists
P-glycoprotein inducers
P-glycoprotein substrates
P-glycoprotein substrates with a Narrow Therapeutic Index
Phenobarbital and similars
Psycholeptics
Pyrimidines
Pyrimidinones
UGT1A1 Inducers
UGT2B7 inducers

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Barbituric acid derivatives
Alternative Parents
N-acyl ureas
/
Diazinanes
/
Benzene and substituted derivatives
/
Dicarboximides
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organonitrogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
Substituents
1,3-diazinane
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Barbiturate
/
Benzenoid
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxylic acid derivative
/
Dicarboximide
/
Hydrocarbon derivative
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
barbiturates (
CHEBI:8069
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Diazines

### Sub Class

Pyrimidines and pyrimidine derivatives

### Direct Parent

Barbituric acid derivatives

### Alternative Parents

N-acyl ureas
/
Diazinanes
/
Benzene and substituted derivatives
/
Dicarboximides
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organonitrogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds

### Substituents

1,3-diazinane
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Barbiturate
/
Benzenoid
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxylic acid derivative
/
Dicarboximide
/
Hydrocarbon derivative

### Molecular Framework

Aromatic heteromonocyclic compounds

### External Descriptors

barbiturates (
CHEBI:8069
)

### Affected organisms

Humans and other mammals

### UNII

YQE403BP4D

### CAS number

50-06-6

### InChI Key

DDBREPKUVSBGFI-UHFFFAOYSA-N

### InChI

InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)

### Synthesis Reference

Tong Sun, Shawn Watson, Rajesh Manchanda, "PHENOBARBITAL SALTS; METHODS OF MAKING; AND METHODS OF USE THEREOF." U.S. Patent US20100035904, issued February 11, 2010.
US20100035904

### General References

Kwan P, Brodie MJ: Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004 Sep;45(9):1141-9. [
Article
]
Taylor S, Tudur Smith C, Williamson PR, Marson AG: Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev. 2001;(4):CD002217. [
Article
]
Tudur Smith C, Marson AG, Williamson PR: Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev. 2003;(1):CD001904. [
Article
]
Kalviainen R, Eriksson K, Parviainen I: Refractory generalised convulsive status epilepticus : a guide to treatment. CNS Drugs. 2005;19(9):759-68. [
Article
]
Booth D, Evans DJ: Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004218. [
Article
]
Pacifici GM: Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. Curr Pediatr Rev. 2016;12(1):48-54. doi: 10.2174/1573397111666151026223914. [
Article
]

### External Links

Human Metabolome Database
HMDB0015305
KEGG Drug
D00506
KEGG Compound
C07434
PubChem Compound
4763
PubChem Substance
46505776
ChemSpider
4599
BindingDB
50021437
RxNav
8134
ChEBI
8069
ChEMBL
CHEMBL40
ZINC
ZINC000095588079
Therapeutic Targets Database
DAP000061
PharmGKB
PA450911
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
UQA
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Phenobarbital

### Human Metabolome Database

HMDB0015305

### KEGG Drug

D00506

### KEGG Compound

C07434

### PubChem Compound

4763

### PubChem Substance

46505776

### ChemSpider

4599

### BindingDB

50021437

### RxNav

8134

### ChEBI

8069

### ChEMBL

CHEMBL40

### ZINC

ZINC000095588079

### Therapeutic Targets Database

DAP000061

### PharmGKB

PA450911

### Guide to Pharmacology

GtP Drug Page

### PDBe Ligand

UQA

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### PDRhealth

PDRhealth Drug Page

### Wikipedia

Phenobarbital

### PDB Entries

6x3w

### MSDS

Download
(53 KB)

### Packagers

Actavis Group
Amend
Apotheca Inc.
Baxter International Inc.
Breckenridge Pharmaceuticals
C.O. Truxton Inc.
Cardinal Health
Carlisle Laboratories Inc.
Century Pharmaceuticals Inc.
Comprehensive Consultant Services Inc.
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Econolab Inc.
Excellium Pharmaceutical Inc.
Group Health Cooperative
Heartland Repack Services LLC
Hikma Pharmaceuticals
Hl Moore Drug Exchange
Hospira Inc.
Kaiser Foundation Hospital
Kraft Pharmaceutical Co. Inc.
Lake Erie Medical and Surgical Supply
Lundbeck Inc.
Major Pharmaceuticals
Mallinckrodt Inc.
Mckesson Corp.
Murfreesboro Pharmaceutical Nursing Supply
Nucare Pharmaceuticals Inc.
Ohm Laboratories Inc.
PD-Rx Pharmaceuticals Inc.
Pharmaceutical Association
Pharmaceutical Utilization Management Program VA Inc.
Pharmacy Service Center
Pharmedix
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepak Systems Inc.
Qualitest
Ranbaxy Laboratories
Remedy Repack
Resource Optimization and Innovation LLC
River's Edge Pharmaceuticals
Stanley Pharmaceuticals Ltd.
UDL Laboratories
United Research Laboratories Inc.
Vintage Pharmaceuticals Inc.
West-Ward Pharmaceuticals

### Dosage Forms

Form
Route
Strength
Elixir
Oral
4 mg / mL
Tablet, extended release
Oral
Tablet, film coated, extended release
Oral
Tablet
Oral
100.000 mg
Solution
Oral
400 mg
Tablet
Oral
10 mg
Solution
Intramuscular; Intravenous
0.2 g
Solution
Parenteral
200 mg
Injection
Parenteral
40 mg
Tablet
Oral
100 mg
Tablet
Oral
50 mg
Injection, solution
Parenteral
100 MG/ML
Injection, solution
Intramuscular
100 MG/2ML
Injection, solution
Intramuscular
30 MG/ML
Solution
Intramuscular; Intravenous
40 mg
Injection, solution
Intramuscular
100 MG
Elixir
Oral
0.3 %
Injection, solution
Intramuscular; Parenteral
200 MG/ML
Syrup
50 MG/10ML
Capsule
Oral
Tablet
Oral
15 mg
Tablet
Oral
30 mg
Tablet
Oral
60 mg
Solution
Oral
5 mg / mL
Elixir
Oral
20 mg/5mL
Elixir
Oral
20.0 mg/5mL
Liquid
Oral
20 mg/5mL
Solution
Oral
20 mg/5mL
Tablet
Oral
Tablet
Oral
100 mg/1
Tablet
Oral
15 mg/1
Tablet
Oral
16.2 mg/1
Tablet
Oral
30 mg/1
Tablet
Oral
32.4 mg/1
Tablet
Oral
60 mg/1
Tablet
Oral
64.8 mg/1
Tablet
Oral
97.2 mg/1
Solution
Oral
30 mg/7.5mL
Solution
Oral
60 mg/15mL
Injection
Intramuscular
130 mg/1mL
Injection
Intramuscular
65 mg/1mL
Injection
Intramuscular; Intravenous
130 mg/1mL
Injection
Intramuscular; Intravenous
65 mg/1mL
Injection
Parenteral
50 MG/ML
Injection, solution
Intramuscular; Intravenous
130 mg/1mL
Injection, solution
Intramuscular; Intravenous
65 mg/1mL
Solution
Intramuscular; Intravenous; Subcutaneous
30 mg / mL
Solution
Intramuscular; Intravenous
120 mg / mL
Solution
Intramuscular; Intravenous
30 mg / mL
Elixir
Oral
Tablet
Oral
Injection
Parenteral
100 MG/ML
Suppository
Rectal
Injection
Intravenous
100 mg/1
Liquid
Oral

### Prices

Unit description
Cost
Unit
Phenobarbital 130 mg/ml vial
4.32USD
ml
Phenobarbital 65 mg/ml vial
1.63USD
ml
Phenobarbital sodium powder
0.36USD
g
Pms-Phenobarbital 100 mg Tablet
0.15USD
tablet
Phenobarbital powder
0.13USD
g
Pms-Phenobarbital 60 mg Tablet
0.11USD
tablet
Phenobarbital 97.2 mg tablet
0.1USD
tablet
Phenobarbital 64.8 mg tablet
0.09USD
tablet
Pms-Phenobarbital 5 mg/ml Elixir
0.09USD
ml
Phenobarbital 16.2 mg tablet
0.08USD
tablet
Phenobarbital 30 mg tablet
0.08USD
tablet
Phenobarbital 32.4 mg tablet
0.08USD
tablet
Pms-Phenobarbital 30 mg Tablet
0.08USD
tablet
Phenobarbital 100 mg tablet
0.07USD
tablet
Pms-Phenobarbital 15 mg Tablet
0.07USD
tablet
PHENobarbital 20 mg/5ml Elixir
0.06USD
ml
Phenobarbital 60 mg tablet
0.03USD
tablet
Phenobarbital 15 mg tablet
0.02USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
174 °C
PhysProp
water solubility
1110 mg/L (at 25 °C)
YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP
1.47
HANSCH,C ET AL. (1995)
pKa
7.3
BUDAVARI,S ET AL. (1996)

### Predicted Properties

Property
Value
Source
Water Solubility
0.276 mg/mL
ALOGPS
logP
1.4
ALOGPS
logP
1.41
Chemaxon
logS
-2.9
ALOGPS
pKa (Strongest Acidic)
7.14
Chemaxon
Physiological Charge
-1
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
2
Chemaxon
Polar Surface Area
75.27 Å
2
Chemaxon
Rotatable Bond Count
2
Chemaxon
Refractivity
59.75 m
3
·mol
-1
Chemaxon
Polarizability
22.59 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9935
Blood Brain Barrier
+
0.9736
Caco-2 permeable
-
0.5561
P-glycoprotein substrate
Substrate
0.5157
P-glycoprotein inhibitor I
Non-inhibitor
0.6472
P-glycoprotein inhibitor II
Non-inhibitor
0.9869
Renal organic cation transporter
Non-inhibitor
0.9235
CYP450 2C9 substrate
Non-substrate
0.6962
CYP450 2D6 substrate
Non-substrate
0.9116
CYP450 3A4 substrate
Non-substrate
0.7702
CYP450 1A2 substrate
Non-inhibitor
0.84
CYP450 2C9 inhibitor
Non-inhibitor
0.9023
CYP450 2D6 inhibitor
Non-inhibitor
0.9593
CYP450 2C19 inhibitor
Non-inhibitor
0.8664
CYP450 3A4 inhibitor
Non-inhibitor
0.9236
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.9164
Ames test
AMES toxic
0.9107
Carcinogenicity
Non-carcinogens
0.7469
Biodegradation
Not ready biodegradable
0.9894
Rat acute toxicity
3.1244 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.99
hERG inhibition (predictor II)
Non-inhibitor
0.9354
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(8.44 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-014i-1940000000-8377cca722b6479ce2fd
GC-MS Spectrum - EI-B
GC-MS
splash10-0udi-5970000000-7bda34bd3bb88b5fd9fd
GC-MS Spectrum - CI-B
GC-MS
splash10-001i-0090000000-55265fc1e12027dc6454
Mass Spectrum (Electron Ionization)
MS
splash10-0uxr-6950000000-193bf296d3e5d1705628
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-001i-0190000000-8cf53cd66a890256ea98
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-001i-1290000000-73d0e0b25f99ffc6a500
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-0016-3950000000-ab62a9483b8a2a65b563
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-0006-0900000000-4121e8dd703c01c1161c
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-0006-0900000000-4976dfc244184e5d627b
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-001i-1890000000-a12eb2be0b05b9f234de
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-03di-1920000000-43ed71cd16bfceef49e6
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-08fr-2900000000-236ae1dab83b15539a86
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053u-3900000000-2a994f0e45c022cca640
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053u-4900000000-066a53ca113150f58406
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-05o3-6900000000-b8f9c9d0f71b6d2c6c2f
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0uy3-8900000000-6bcd457bfff85f05fe9c
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0udi-9500000000-0ecfff7e43e9e78d677e
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0uxs-9300000000-7413ad1c764a1ae4a98e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-0390000000-f2147d068e18223694c5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9310000000-8f28ab4d44583146115c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1900000000-3ee2f0a4c65cdb33c0aa
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9000000000-b05d6bfef8dfbacd745d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-3940000000-bf59676229ff02f2fa16
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9120000000-73e8d9efbc75ac46d257
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-0390000000-b80fd29f5e672b9a3083
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9210000000-8bc75358f3b56e3c0432
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1900000000-96f4625a08add32dcca1
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9000000000-fd502df51e9ef52baa4e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9110000000-9ea8c84e4188051e5b81
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1930000000-c4d9938ef20de9f70a0d
1H NMR Spectrum
1D NMR
Not Applicable
13C NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
157.4845834
predicted
DarkChem Lite v0.1.0
[M-H]-
159.3932
predicted
DeepCCS 1.0 (2019)
[M-H]-
157.4845834
predicted
DarkChem Lite v0.1.0
[M-H]-
159.3932
predicted
DeepCCS 1.0 (2019)
[M+H]+
158.2351834
predicted
DarkChem Lite v0.1.0
[M+H]+
161.75119
predicted
DeepCCS 1.0 (2019)
[M+H]+
158.2351834
predicted
DarkChem Lite v0.1.0
[M+H]+
161.75119
predicted
DeepCCS 1.0 (2019)
[M+Na]+
157.8849834
predicted
DarkChem Lite v0.1.0
[M+Na]+
167.84435
predicted
DeepCCS 1.0 (2019)
[M+Na]+
157.8849834
predicted
DarkChem Lite v0.1.0
[M+Na]+
167.84435
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Inducer

### General Function

ATP-dependent transporter of the ATP-binding cassette (ABC) family that binds and hydrolyzes ATP to enable active transport of various substrates including many drugs, toxicants and endogenous compound across cell membranes. Transports a wide variety of conjugated organic anions such as sulfate-, glucuronide- and glutathione (GSH)-conjugates of endo- and xenobiotics substrates (PubMed:10220572, PubMed:10421658, PubMed:11500505, PubMed:16332456). Mediates hepatobiliary excretion of mono- and bis-glucuronidated bilirubin molecules and therefore play an important role in bilirubin detoxification (PubMed:10421658). Also mediates hepatobiliary excretion of others glucuronide conjugates such as 17beta-estradiol 17-glucosiduronic acid and leukotriene C4 (PubMed:11500505). Transports sulfated bile salt such as taurolithocholate sulfate (PubMed:16332456). Transports various anticancer drugs, such as anthracycline, vinca alkaloid and methotrexate and HIV-drugs such as protease inhibitors (PubMed:10220572, PubMed:11500505, PubMed:12441801). Confers resistance to several anti-cancer drugs including cisplatin, doxorubicin, epirubicin, methotrexate, etoposide and vincristine (PubMed:10220572, PubMed:11500505)

### Specific Function

ABC-type glutathione S-conjugate transporter activity

### Gene Name

ABCC2

### Uniprot ID

Q92887

### Uniprot Name

ATP-binding cassette sub-family C member 2

### Molecular Weight

174205.64 Da

### Curator comments

Enzyme action based on in vivo study in rats. Only one study supports this currently.

`,
  "isomerdesign": `# Phenobarbital
*Source: https://isomerdesign.com/PiHKAL/explore.php?id=3991*

## Chemical Data

**IUPAC Name:** 5-Ethyl-5-phenyl-1,3-diazinane-2,4,6-trione

**Molecular Formula:** C12H12N2O3

**Molecular Weight:** 232.235

**SMILES:** \`CCC1(C(=O)NC(=O)NC1=O)c1ccccc1\`

**InChI:** \`InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)\`

## External References

- [](https://en.wikipedia.org/wiki/Markush_structure)
- [4599](https://www.chemspider.com/Chemical-Structure.4599.html/)
- [4763](https://pubchem.ncbi.nlm.nih.gov/compound/4763)
- [Q407241](https://www.wikidata.org/wiki/Q407241)
- [Phenobarbital](https://en.wikipedia.org/wiki/Phenobarbital)
`,
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/Phenobarbital",
  "experiencesUrl": "https://www.reddit.com/search/?q=Phenobarbital",
  "name": "Phenobarbital",
  "aliases": [
    "luminal",
    "pheno",
    "phenobarb",
    "phenobarbitone"
  ],
  "aliasesStr": "luminal,pheno,phenobarb,phenobarbitone",
  "summary": "CNS depressant that is used mostly for insomnia (In older patients) and epliepsy (in younger patients) And it a very strong narcotic, that can be taken most ways. It's used less as \\"safer\\" alternatives have been made (Benzodiazepines).",
  "reagents": null,
  "classes": {
    "chemical": [
      "Barbiturates"
    ],
    "psychoactive": [
      "Depressant"
    ]
  },
  "toxicity": [
    "moderate toxicity",
    "potentially lethal when mixed with depressants like alcohol or opioids"
  ],
  "addictionPotential": "extremely physically and psychologically addictive",
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "25 mg"
        },
        {
          "name": "Light",
          "value": "50 - 100 mg"
        },
        {
          "name": "Common",
          "value": "100 - 150 mg"
        },
        {
          "name": "Strong",
          "value": "150 - 300 mg"
        },
        {
          "name": "Heavy",
          "value": "300 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.25 - 1.0 hours"
        },
        {
          "name": "Come up",
          "value": "1.0 - 2.0 hours"
        },
        {
          "name": "Peak",
          "value": "4.0 - 6.0 hours"
        },
        {
          "name": "Offset",
          "value": "12.0 - 24.0 hours"
        },
        {
          "name": "Total",
          "value": "4.0 - 6.0 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 48.0 hours"
        }
      ]
    },
    {
      "name": "Intravenous",
      "duration": [
        {
          "name": "Onset",
          "value": "0.02 - 0.08 hours"
        },
        {
          "name": "Duration",
          "value": "4.0 - 6.0 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 24.0 hours"
        }
      ]
    }
  ],
  "interactions": null,
  "effects": "Emotion suppression, Dizziness, Physical euphoria, Delusion, Cognitive euphoria, Thought deceleration, Disinhibition, Sedation, Motor control loss, Respiratory depression, Decreased blood pressure, Muscle relaxation, Anxiety suppression, Compulsive redosing, Amnesia, Visual acuity suppression, Decreased libido, Seizure suppression, Analysis depression, Language depression",
  "categorized_effects": {
    "Physical effects": [
      "Dizziness",
      "Physical euphoria",
      "Sedation",
      "Motor control loss",
      "Respiratory depression",
      "Decreased blood pressure",
      "Muscle relaxation",
      "Seizure suppression"
    ],
    "Mental effects": [
      "Emotion suppression",
      "Delusion",
      "Cognitive euphoria",
      "Thought deceleration",
      "Disinhibition",
      "Anxiety suppression",
      "Amnesia",
      "Analysis depression",
      "Language depression"
    ],
    "Sensory effects": [
      "Visual acuity suppression",
      "Decreased libido"
    ],
    "Uncategorized effects": [
      "Compulsive redosing"
    ]
  }
}`,
  "psychonautwiki": `# Phenobarbital
*Source: https://psychonautwiki.org/wiki/Phenobarbital*

## Dosage & Duration

### Oral

**Dosage:**
- Threshold: 25 mg
- Light: 50 - 100 mg
- Common: 100 - 150 mg
- Strong: 150 - 300 mg
- Heavy: 300 mg +

**Duration:**
- Total: 4 - 6 hours
- Onset: 15 - 60 minutes
- Come up: 1 - 2 hours
- Peak: 4 - 6 hours
- Offset: 12 - 24 hours
- After effects: 1 - 48 hours
**Death may occur when [barbiturates](https://psychonautwiki.org/wiki/Barbiturate) are combined with [depressants](https://psychonautwiki.org/wiki/Depressants) such as [opiates](https://psychonautwiki.org/wiki/Opiates) , [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepines) , [gabapentinoids](https://psychonautwiki.org/wiki/Gabapentinoids) , [thienodiazepines](https://psychonautwiki.org/wiki/Thienodiazepines) , [alcohol](https://psychonautwiki.org/wiki/Alcohol) or other [GABAergic substances](https://psychonautwiki.org/wiki/GABA#GABA_receptors) .**
 
It is strongly discouraged to consume [moderate](https://psychonautwiki.org/wiki/Moderate) to [heavy](https://psychonautwiki.org/wiki/Heavy) dosages of these substances together.
**Phenobarbital** , also known as **phenobarbitone** in British English and by the brand name **Luminal** , is a long-acting psychoactive drug of the [barbiturate](https://psychonautwiki.org/wiki/Barbiturate) class which produces powerful anxiolytic, hypnotic, muscle relaxant and amnesic effects. Phenobarbital is used medically as an [anticonvulsant](https://psychonautwiki.org/wiki/Seizure_suppression) , and occasionally in the short term treatment of [insomnia](https://psychonautwiki.org/wiki/Insomnia) . Phenobarbital works in a similar fashion to [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepine) , however barbiturates bind to a distinct allosteric site on the GABA A receptor.

Compared to other barbiturates such as [pentobarbital](https://psychonautwiki.org/wiki/Pentobarbital) , phenobarbital has an extremely slow elimination and long duration of action, similar to [diazepam](https://psychonautwiki.org/wiki/Diazepam) , which makes it ideal for the treatment of epilepsy.

Phenobarbital, like most long-acting barbiturates, can be deemed moderately addictive. The abrupt discontinuation of phenobarbital in dependent individuals may be life-threatening and lead to [seizures](https://psychonautwiki.org/wiki/Seizure) and even death . Phenobarbital drastically enhances the effects of other [depressants](https://psychonautwiki.org/wiki/Depressant) such as [alcohol](https://psychonautwiki.org/wiki/Alcohol) , and concurrent use may lead to [respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression) and possibly death.

According to many sources, it is substantially more powerful than sister-substances pentobarbital or [secobarbital](https://psychonautwiki.org/wiki/Secobarbital) ' ' , with a dosage convertion ratio of 1:3 in order to achieve equal depressant effects. The product is nonetheless consumed in very high doses as an anti-epileptic substance, as is also [clonazepam](https://psychonautwiki.org/wiki/Clonazepam) , which has largely replaced phenobarbital in this context.

## Chemistry

Phenobarbital is a drug of the [barbiturate](https://psychonautwiki.org/wiki/Barbiturate) class. Barbiturate drugs contain the backbone of barbituric acid. Phenobarbital has a 5-ethyl, 5-phenyl substitution on the 5-position of the barbituric acid backbone which gives it its unique pharmacological effects. Phenobarbital empirical formula is C 12 H 12 N 2 O 3 and has a molar mass of 232.235 grams per mole.

Phenobarbital appears as odorless white crystalline powder or colorless crystals. A saturated aqueous solution is acid to litmus (approximately pH 5). Slightly bitter taste. Aqueous solutions of "phenobarbital" sodium are not generally stable. The drug is more stable in polyethylene glycol or propylene glycol.

## Pharmacology

Barbiturates behave similarly to [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepine) . Phenobarbital binds to an allosteric site on the GABA A receptor and potentiates the effects of the endogenous ligand, [gamma-aminobutyric acid](https://psychonautwiki.org/wiki/GABA) . When barbiturates bind to the GABA A receptor, it causes the ion pore to open for extended periods of time, causing an increase of intracellular chlorine ion concentrations. As this site is the most prolific inhibitory receptor set within the brain, its modulation results in the [sedating](https://psychonautwiki.org/wiki/Sedating) (or [calming effects](https://psychonautwiki.org/wiki/Anxiety_suppression) ) of barbiturates on the nervous system. Phenobarbital's biological half life is 53-118 hours. It is metabolized by the liver and excreted by the kidneys and intestines.

Phenobarbital has an oral bioavailability of about 90%. Peak plasma concentrations (C max ) are reached eight to 12 hours after oral administration. It is one of the longest-acting barbiturates available – it remains in the body for a very long time (half-life of two to seven days) and has very low protein binding (20 to 45%). Phenobarbital is metabolized by the liver, mainly through hydroxylation and glucuronidation, and induces many isozymes of the cytochrome P450 system. Cytochrome P450 2B6 (CYP2B6) is specifically induced by phenobarbital via the CAR/RXR nuclear receptor heterodimer. It is excreted primarily by the kidneys.

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Sedation](https://psychonautwiki.org/wiki/Sedation)** - In terms of energy level alterations, this drug has the potential to be extremely sedating and often results in an overwhelmingly lethargic state. At higher levels, this causes users to suddenly feel as if they are extremely sleep deprived and have not slept for days, forcing them to sit down and generally feel as if they are constantly on the verge of passing out instead of engaging in physical activities. This sense of sleep deprivation increases proportional to dosage and eventually becomes powerful enough to force a person into complete unconsciousness.
- **[Motor control loss](https://psychonautwiki.org/wiki/Motor_control_loss)**
- **[Muscle relaxation](https://psychonautwiki.org/wiki/Muscle_relaxation)**
- **[Dizziness](https://psychonautwiki.org/wiki/Dizziness)**
- **[Decreased blood pressure](https://psychonautwiki.org/wiki/Decreased_blood_pressure)** - Barbiturates may decrease blood pressure in some individuals and have occasionally been used to reduce intracranial pressure.
- **[Respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression)**
- **[Seizure suppression](https://psychonautwiki.org/wiki/Seizure_suppression)**
- **[Physical euphoria](https://psychonautwiki.org/wiki/Physical_euphoria)** - Compared to short-acting barbiturates such as [pentobarbital](https://psychonautwiki.org/wiki/Pentobarbital) and [secobarbital](https://psychonautwiki.org/wiki/Secobarbital) , this effect is quite weak.
- **[Decreased libido](https://psychonautwiki.org/wiki/Decreased_libido)** ### Visual effects
 
- - **[Acuity suppression](https://psychonautwiki.org/wiki/Acuity_suppression)** - Like many [depressants](https://psychonautwiki.org/wiki/Depressant) , high doses of phenobarbital may cause blurred vision. ### Cognitive effects
 
- - **[Anxiety suppression](https://psychonautwiki.org/wiki/Anxiety_suppression)**
- **[Cognitive euphoria](https://psychonautwiki.org/wiki/Cognitive_euphoria)** - Compared to short-acting barbiturates such as [pentobarbital](https://psychonautwiki.org/wiki/Pentobarbital) and [secobarbital](https://psychonautwiki.org/wiki/Secobarbital) , this effect is quite weak. The feeling itself can be described as an extremely strong feeling of relaxed contentment.
- **[Thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration)**
- **[Analysis suppression](https://psychonautwiki.org/wiki/Analysis_suppression)**
- **[Disinhibition](https://psychonautwiki.org/wiki/Disinhibition)**
- **[Amnesia](https://psychonautwiki.org/wiki/Amnesia)**
- **[Language suppression](https://psychonautwiki.org/wiki/Language_suppression)** - At higher doses, phenobarbital is known to cause slurred speech.
- **[Compulsive redosing](https://psychonautwiki.org/wiki/Compulsive_redosing)**
- **[Emotion suppression](https://psychonautwiki.org/wiki/Emotion_suppression)** - Although this compound primarily suppresses anxiety, it also dulls other emotions in a manner which is distinct but less intensive than that of [antipsychotics](https://psychonautwiki.org/wiki/Antipsychotic) .
- **[Delusions of sobriety](https://psychonautwiki.org/wiki/Delusions)** - This is the false belief that one is perfectly sober despite obvious evidence to the contrary such as severe cognitive impairment and an inability to fully communicate with others. It most commonly occurs at heavy dosages.
### Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) . Additional experience reports can be found here:

- [Erowid Experience Vaults: Phenobarbital](https://erowid.org/experiences/subs/exp_Barbiturates_Phenobarbital.shtml)

## Toxicity and harm potential

Phenobarbital likely has moderate toxicity relative to dose. However, phenobarbital is potentially [lethal](https://psychonautwiki.org/wiki/Respiratory_depression) when mixed with [depressants](https://psychonautwiki.org/wiki/Depressants) like [alcohol](https://psychonautwiki.org/wiki/Alcohol) or [opioids](https://psychonautwiki.org/wiki/Opioids) . Phenobarbital has a higher risk of death or serious adverse effects associated with concurrent [depressant](https://psychonautwiki.org/wiki/Depressant) use than other drugs such as benzodiazepines. There have been studies linking the use of barbiturates, particularly phenobarbital, with the development of cancer .

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this drug.

### Tolerance and addiction potential

Phenobarbital is extremely physically and psychologically addictive. Barbiturate withdrawal is medically serious and can potentially cause a life-threatening withdrawal syndrome that can cause [seizures](https://psychonautwiki.org/wiki/Seizure) , [psychosis](https://psychonautwiki.org/wiki/Psychosis) , and death. Drugs which lower the seizure threshold such as [tramadol](https://psychonautwiki.org/wiki/Tramadol) and [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) should be avoided during withdrawal.

Tolerance will develop to the sedative-hypnotic effects of phenobarbital after prolonged use. It is unknown exactly how long it takes for tolerance to reach baseline. Phenobarbital presents cross-tolerance with all barbiturates, meaning that after its consumption all barbiturates will have a reduced effect.

### Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be harmless in low doses of each but still increase the potential risk of death. [Independent research](https://www.google.com/) should always be done to ensure that a combination of two or more substances is safe before consumption.

- **[Depressants](https://psychonautwiki.org/wiki/Depressants)** ( *[1,4-Butanediol](https://psychonautwiki.org/wiki/1,4-Butanediol) , [2-methyl-2-butanol](https://psychonautwiki.org/wiki/2-methyl-2-butanol) , [alcohol](https://psychonautwiki.org/wiki/Alcohol) , [barbiturates](https://psychonautwiki.org/wiki/Barbiturates) , [GHB](https://psychonautwiki.org/wiki/GHB) / [GBL](https://psychonautwiki.org/wiki/GBL) , [methaqualone](https://psychonautwiki.org/wiki/Methaqualone) , [opioids](https://psychonautwiki.org/wiki/Opioids)* ) - This combination can result in dangerous or even fatal levels of [respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression) . These substances potentiate the [muscle relaxation](https://psychonautwiki.org/wiki/Muscle_relaxation) , [sedation](https://psychonautwiki.org/wiki/Sedation) and [amnesia](https://psychonautwiki.org/wiki/Amnesia) caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should try to fall asleep in the [recovery position](https://psychonautwiki.org/wiki/Recovery_position) or have a friend move them into it.
- **[Dissociatives](https://psychonautwiki.org/wiki/Dissociatives)** - This combination can lead to an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [recovery position](https://psychonautwiki.org/wiki/Recovery_position) or have a friend move them into it.
- **[Stimulants](https://psychonautwiki.org/wiki/Stimulants)** - It is unsafe to combine barbiturates with [stimulants](https://psychonautwiki.org/wiki/Stimulant) due to the risk of excessive intoxication. Stimulants decrease the [sedative](https://psychonautwiki.org/wiki/Sedation) effect of barbiturates, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of barbiturates will be considerably increased, leading to intensified [disinhibition](https://psychonautwiki.org/wiki/Disinhibition) as well as other effects. If combined, one should strictly limit themselves to only dosing a certain amount of barbiturates per hour. This combination can also potentially result in severe dehydration if hydration is not monitored.

### Overdose

Barbiturate overdose may occur when a barbiturate is taken in extremely heavy quantities or concurrently with other depressants. This is particularly dangerous with other GABAergic depressants such as [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepine) and [alcohol](https://psychonautwiki.org/wiki/Alcohol) since they work in a similar fashion, but bind to distinct allosteric sites on the GABA A receptor, thus their effects potentiate one another. Benzodiazepines increase the frequency in which the chlorine ion pore opens on the GABA A receptor while barbiturates increase the duration in which they are open, meaning when both are consumed, the ion pore will open more frequently and stay open longer . Barbiturate overdose is a medical emergency that may lead to a coma, permanent brain injury or death if not treated promptly and properly. Barbiturate overdose has an increased frequency of serious adverse effects when compared to other depressants.

Symptoms of a barbiturate overdose may include severe [thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration) , [slurred speech](https://psychonautwiki.org/wiki/Language_suppression) , [confusion](https://psychonautwiki.org/wiki/Confusion) , [delusions](https://psychonautwiki.org/wiki/Delusions) , [respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression) , coma or death .

## Legal status

Internationally, phenobarbital is listed in Schedule IV of the UN Convention on Psychotropic Substances.

- **Australia** : Phenobarbitone is listed in Schedule 4, making it a prescription only medicine.
- **Canada** : Phenobarbital is a Schedule IV controlled substance.
- **Germany** : Phenobarbital is controlled under Anlage III BtMG ( *Narcotics Act, Schedule III* ). It can only be prescribed on a narcotic prescription form, except preparations which contain up to 10% or up to 300 mg phenobarbital in each dosage form.
- **Russia** : Phenobarbital is a Schedule III controlled substance since 2013. but phenobarbital is also found in the medicines [Corvalol](http://en.wikipedia.org/wiki/Corvalol) or Valocordin, which is dispensed without a doctor’s prescription.
- **Switzerland** : Phenobarbital is a controlled substance specifically named under Verzeichnis B. Medicinal use is permitted.
- **United Kingdom** : Phenobarbitone is a Class B controlled substance.
- **United States** : Phenobarbital is a Schedule IV controlled substance.

## See also

- [Depressants](https://psychonautwiki.org/wiki/Depressant)
- [Benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepine)
- [GABA](https://psychonautwiki.org/wiki/GABA)

## External links

- [Phenobarbital (Wikipedia)](https://en.wikipedia.org/wiki/Phenobarbital)
- [Phenobarbital (TiHKAL / Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=3991)
- [Phenobarbital (DrugBank)](https://go.drugbank.com/drugs/DB01174)

## References
1. ↑ [Risks of Combining Depressants - TripSit](https://tripsit.me/combining-depressants/)
2. ↑ Sarrecchia, C., Sordillo, P., Conte, G., Rocchi, G. (December 1998). "[Barbiturate withdrawal syndrome: a case associated with the abuse of a headache medication]".*Annali Italiani Di Medicina Interna: Organo Ufficiale Della Societa Italiana Di Medicina Interna*.**13**(4): 237–239.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0393-9340](//www.worldcat.org/issn/0393-9340).
3. ↑ [Benzodiazepine Equivalents Conversion Calculator - ClinCalc.com](https://clincalc.com/Benzodiazepine/)
4. ↑ [Benzodiazepine Equivalents](https://fpnotebook.com/psych/cd/BnzdzpnEqvlnts.htm)
5. ↑ Inada, T., Inagaki, A. (August 2015).["Psychotropic dose equivalence in Japan: Psychotropic dose equivalence in Japan"](https://onlinelibrary.wiley.com/doi/10.1111/pcn.12275).*Psychiatry and Clinical Neurosciences*.**69**(8): 440–447.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1111/pcn.12275](//doi.org/10.1111%2Fpcn.12275).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1323-1316](//www.worldcat.org/issn/1323-1316).
6. ↑ National Toxicology Program, Institute of Environmental Health Sciences, National Institutes of Health (NTP). 1992. National Toxicology Program Chemical Repository Database. Research Triangle Park, North Carolina.
7. ↑ Snow, E. K., American Society of Health-System Pharmacists (2009).*AHFS drug information, 2009*. American Society of Health-System Pharmacists.[ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number)[9781585282272](http://en.wikipedia.org/wiki/Special:BookSources/9781585282272).
8. ↑ Flynn, S., Babi, M. A. (2017). "Pharmacology and Therapeutics for Dentistry".[Anticonvulsants](https://linkinghub.elsevier.com/retrieve/pii/B9780323393072000126). Elsevier. pp. 176–192.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/B978-0-323-39307-2.00012-6](//doi.org/10.1016%2FB978-0-323-39307-2.00012-6).[ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number)[9780323393072](http://en.wikipedia.org/wiki/Special:BookSources/9780323393072).
9. ↑ Roberts, I., Sydenham, E. (12 December 2012). Cochrane Injuries Group, ed.["Barbiturates for acute traumatic brain injury"](https://doi.wiley.com/10.1002/14651858.CD000033.pub2).*Cochrane Database of Systematic Reviews*.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/14651858.CD000033.pub2](//doi.org/10.1002%2F14651858.CD000033.pub2).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1465-1858](//www.worldcat.org/issn/1465-1858).
10. ↑ Nutt, D., King, L. A., Saulsbury, W., Blakemore, C. (24 March 2007).["Development of a rational scale to assess the harm of drugs of potential misuse"](https://www.sciencedirect.com/science/article/pii/S0140673607604644).*The Lancet*.**369**(9566): 1047–1053.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0140-6736(07)60464-4](//doi.org/10.1016%2FS0140-6736%2807%2960464-4).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0140-6736](//www.worldcat.org/issn/0140-6736).
11. ↑ Friedman, G. D., Habel, L. A. (1 June 1999).["Barbiturates and lung cancer: a re-evaluation"](https://academic.oup.com/ije/article-lookup/doi/10.1093/ije/28.3.375).*International Journal of Epidemiology*.**28**(3): 375–379.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1093/ije/28.3.375](//doi.org/10.1093%2Fije%2F28.3.375).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0300-5771](//www.worldcat.org/issn/0300-5771).
12. ↑ Twyman, R. E., Rogers, C. J., Macdonald, R. L. (March 1989). "Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital".*Annals of Neurology*.**25**(3): 213–220.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/ana.410250302](//doi.org/10.1002%2Fana.410250302).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0364-5134](//www.worldcat.org/issn/0364-5134).
13. ↑ [Barbiturate intoxication and overdose: MedlinePlus Medical Encyclopedia](https://medlineplus.gov/ency/article/000951.htm)
14. ↑ UN Convention on Psychotropic Substances | [https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/1971_Schedules/Revision1_2015/ST_CND_1_ADD2_Rev1_e_V1600359.pdf](https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/1971_Schedules/Revision1_2015/ST_CND_1_ADD2_Rev1_e_V1600359.pdf)
15. ↑ Controlled Drugs | [http://www.health.nsw.gov.au/pharmaceutical/Documents/poisons-list-alpha.pdf](http://www.health.nsw.gov.au/pharmaceutical/Documents/poisons-list-alpha.pdf)
16. ↑ Branch, L. S. (2022),[Consolidated federal laws of Canada, Controlled Drugs and Substances Act](https://laws-lois.justice.gc.ca/eng/acts/c-38.8/page-15.html)
17. ↑ 17.0 17.1 ["Anlage III BtMG"](https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 26, 2019.
18. ↑ [Постановление Правительства РФ от 04.02.2013 N 78 “О внесении изменений в некоторые акты Правительства Российской Федерации” - КонсультантПлюс](https://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=LAW&n=141744&dst=100005&date=02.12.2019)
19. ↑ [Государственный реестр лекарственных средств](https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fbbb0394-bac0-4f25-820a-a11fed50bbd7&t=)
20. ↑ ["Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html)(in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
21. ↑ [Drugs penalties](https://www.gov.uk/penalties-drug-possession-dealing)
22. ↑ DEA Schedule IV Drugs | [https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf](https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf)NewPP limit report Cached time: 20251218075721 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.019 seconds CPU time usage: 0.262 seconds Real time usage: 0.580 seconds Preprocessor visited node count: 1668/1000000 Post‐expand include size: 101940/2097152 bytes Template argument size: 11474/2097152 bytes Highest expansion depth: 12/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 23552/5000000 bytes Lua time usage: 0.240/7 seconds Lua virtual size: 7.88 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 512.769 1 -total 25.04% 128.394 8 Template:Citation 22.60% 115.864 6 Template:Cite_journal 14.13% 72.435 1 Template:Headerpanel 13.39% 68.674 1 Template:Warning/Barbiturates 12.89% 66.091 1 Template:SubstanceBox/Phenobarbital 12.71% 65.181 1 Template:GenericPanel/warning 12.10% 62.069 1 Template:SubstanceBox 12.00% 61.525 1 Template:GenericPanel 7.43% 38.085 2 Template:Cite_book`,
  "tripsit-factsheets": `# Phenobarbital
*Source: https://tripbot.tripsit.me/api/tripsit/getDrug/phenobarbital*

## Classification
- **Categories:** depressant, habit-forming, barbiturate
- **Also known as:** pheno, phenobarbitone, luminal

## Dosage

### Oral
- **Common:** 100-150mg
- **Light:** 50-100mg
- **Strong:** 150-300mg

## Duration
- **Onset:** {'_unit': 'minutes', 'Intravenous': '1-5', 'Oral': '15-45'}
- **Duration:** {'_unit': 'hours', 'Intravenous': '4-6', 'Oral': '5-8'}
- **After Effects:** 1-24 hours
`,
  "wikipedia": `# Phenobarbital
*Source: https://en.wikipedia.org/wiki/Phenobarbital*

Phenobarbital, also known as phenobarbitone or phenobarb, sold under the brand name Luminal among others, is a medication of the barbiturate type. It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries. In the developed world, it is commonly used to treat seizures in young children, while other medications are generally used in older children and adults. It is also used for veterinary purposes.
It may be administered by slow intravenous infusion (IV infusion), intramuscularly (IM), or orally (swallowed by mouth). Subcutaneous administration is not recommended. The IV or IM (injectable forms) may be used to treat status epilepticus if other drugs fail to achieve satisfactory results. Phenobarbital is occasionally used to treat insomnia, anxiety, and benzodiazepine withdrawal (as well as withdrawal from certain other drugs in specific circumstances), and prior to surgery as an anxiolytic and to induce sedation. It usually begins working within five minutes when used intravenously and half an hour when administered orally. Its effects last for between four hours and two days.
Potentially serious side effects include a decreased level of consciousness and respiratory depression. There is potential for both abuse and withdrawal following long-term use. It may also increase the risk of suicide.
It is pregnancy category D in Australia, meaning that it may cause harm when taken during pregnancy. If used during breastfeeding it may result in drowsiness in the baby. Phenobarbital works by increasing the activity of the inhibitory neurotransmitter GABA.
Phenobarbital was discovered in 1912 and is the oldest still commonly used anti-seizure medication. It is on the World Health Organization's List of Essential Medicines.

## Medical uses

Phenobarbital is used in the treatment of all types of seizures, except absence seizures. It is no less effective at seizure control than phenytoin, but phenobarbital is not as well tolerated. Phenobarbital may provide a clinical advantage over carbamazepine for treating partial onset seizures. Carbamazepine may provide a clinical advantage over phenobarbital for generalized onset tonic-clonic seizures.
The first-line drugs for treatment of status epilepticus are benzodiazepines, such as lorazepam, clonazepam, midazolam, or diazepam. If these fail, then phenytoin may be used, with phenobarbital being an alternative in the US (favored in infants), but used only third-line in the UK. Failing that, the only treatment is anaesthesia in intensive care. The World Health Organization (WHO) gives phenobarbital a first-line recommendation in the developing world and it is commonly used there.
Phenobarbital is the first-line choice for the treatment of neonatal seizures. Concerns that neonatal seizures in themselves could be harmful make most physicians treat them aggressively. No reliable evidence, though, supports this approach.
Phenobarbital is sometimes used for alcohol detoxification and benzodiazepine detoxification for its sedative and anti-convulsant properties. The benzodiazepines chlordiazepoxide (Librium) and oxazepam (Serax) have largely replaced phenobarbital for detoxification.
Phenobarbital is useful for insomnia and anxiety.

### Other uses

Phenobarbital properties can effectively reduce tremors and seizures associated with abrupt withdrawal from benzodiazepines.
Phenobarbital is occasionally prescribed in low doses to aid in the conjugation of bilirubin in people with Crigler–Najjar syndrome, type II, or in people with Gilbert's syndrome. In infants suspected of neonatal biliary atresia, phenobarbital is used in preparation for a 99mTc-IDA hepatobiliary (HIDA; hepatobiliary 99mTc-iminodiacetic acid) study that differentiates atresia from hepatitis or cholestasis.
In massive doses, phenobarbital is prescribed to terminally ill people to allow them to end their life through physician-assisted suicide.
Like other barbiturates, phenobarbital can be used recreationally, but this is reported to be relatively infrequent.
The synthesis of a photoswitchable analog (DASA-barbital) and phenobarbital has been described for use as a research compound in photopharmacology.

## Side effects

Sedation and hypnosis are the principal side effects (occasionally, they are also the intended effects) of phenobarbital. Central nervous system effects, such as dizziness, nystagmus and ataxia, are also common. In elderly patients, it may cause excitement and confusion, while in children, it may result in paradoxical hyperactivity.
Phenobarbital is a cytochrome P450 hepatic enzyme inducer. It binds transcription factor receptors that activate cytochrome P450 transcription, thereby increasing its amount and thus its activity. Caution is to be used with children. Among anti-convulsant drugs, behavioural disturbances occur most frequently with clonazepam and phenobarbital.

## Contraindications

Acute intermittent porphyria, hypersensitivity to any barbiturate, prior dependence on barbiturates, severe respiratory insufficiency (as with chronic obstructive pulmonary disease), severe liver failure, pregnancy, and breastfeeding are contraindications for phenobarbital use.

## Overdose

Phenobarbital causes a depression of the body's systems, mainly the central and peripheral nervous systems. Thus, the main characteristic of phenobarbital overdose is a "slowing" of bodily functions, including decreased consciousness (even coma), bradycardia, bradypnea, hypothermia, and hypotension (in massive overdoses). Overdose may also lead to pulmonary edema and acute renal failure as a result of shock and can result in death.
The electroencephalogram (EEG) of a person with phenobarbital overdose may show a marked decrease in electrical activity, to the point of mimicking brain death. This is due to profound depression of the central nervous system and is usually reversible.
Treatment of phenobarbital overdose is supportive, and mainly consists of the maintenance of airway patency (through endotracheal intubation and mechanical ventilation), correction of bradycardia and hypotension (with intravenous fluids and vasopressors, if necessary), and removal of as much drug as possible from the body. In very large overdoses, multi-dose activated charcoal is a mainstay of treatment as the drug undergoes enterohepatic recirculation. Urine alkalization (achieved with sodium bicarbonate) enhances renal excretion. Hemodialysis is effective in removing phenobarbital from the body and may reduce its half-life by up to 90%. No specific antidote for barbiturate poisoning is available.

## Mechanism of action

Phenobarbital acts as an allosteric modulator which extends the amount of time the chloride ion channel is open by interacting with GABAA receptor subunits. Through this action, phenobarbital increases the flow of chloride ions into the neuron which decreases the excitability of the post-synaptic neuron. Hyperpolarizing this post-synaptic membrane leads to a decrease in the general excitatory aspects of the post-synaptic neuron. By making it harder to depolarize the neuron, the threshold for the action potential of the post-synaptic neuron will be increased.
Direct blockade of glutamatergic AMPA and kainate receptors are also believed to contribute to the hypnotic/anticonvulsant effect that is observed with phenobarbital.

## Pharmacokinetics

Phenobarbital has an oral bioavailability of about 90%. Peak plasma concentrations (Cmax) are reached eight to 12 hours after oral administration. It is one of the longest-acting barbiturates available – it remains in the body for a very long time (half-life of two to seven days) and has very low protein binding (20 to 45%). Phenobarbital is metabolized by the liver, mainly through hydroxylation and glucuronidation and induces many isozymes of the cytochrome P450 system. Cytochrome P450 2B6 (CYP2B6) is specifically induced by phenobarbital via the CAR/RXR nuclear receptor heterodimer. It is excreted primarily by the kidneys.

## History

The first barbiturate drug, barbital, was synthesized in 1902 by German chemists Emil Fischer and Joseph von Mering and was first marketed as Veronal by Friedr. Bayer et comp. By 1904, several related drugs, including phenobarbital, had been synthesized by Fischer. Phenobarbital was brought to market in 1912 by the drug company Bayer as the brand Luminal. It remained a commonly prescribed sedative and hypnotic until the introduction of benzodiazepines in the 1960s.
Phenobarbital's soporific, sedative and hypnotic properties were well known in 1912, but it was not yet known to be an effective anti-convulsant. The young doctor Alfred Hauptmann gave it to his epilepsy patients as a tranquilizer and discovered their seizures were susceptible to the drug. Hauptmann performed a careful study of his patients over an extended period. Most of these patients were using the only effective drug then available, bromide, which had terrible side effects and limited efficacy. On phenobarbital, their epilepsy was much improved: The worst patients had fewer and lighter seizures and some patients became seizure-free. In addition, they improved physically and mentally as bromides were removed from their regimen. Patients who had been institutionalised due to the severity of their epilepsy were able to leave and, in some cases, resume employment. Hauptmann dismissed concerns that its effectiveness in stalling seizures could lead to patients developing a build-up that needed to be "discharged". As he expected, withdrawal of the drug led to an increase in seizure frequency – it was not a cure. The drug was quickly adopted as the first widely effective anti-convulsant, though World War I delayed its introduction in the U.S.
In 1939, a German family asked Adolf Hitler to have their disabled son killed; the five-month-old boy was given a lethal dose of Luminal after Hitler sent his own doctor to examine him. A few days later 15 psychiatrists were summoned to Hitler's Chancellery and directed to commence a clandestine program of involuntary euthanasia.
In 1940, at a clinic in Ansbach, Germany, around 50 intellectually disabled children were injected with Luminal and killed that way. A plaque was erected in their memory in 1988 in the local hospital at Feuchtwanger Strasse 38, although a newer plaque does not mention that patients were killed using barbiturates on site. Luminal was used in the Nazi children's euthanasia program until at least 1943.
Phenobarbital was used to treat neonatal jaundice by increasing liver metabolism and thus lowering bilirubin levels. In the 1950s, phototherapy was discovered, and became the standard treatment.
Phenobarbital was used for over 25 years as prophylaxis in the treatment of febrile seizures. Although an effective treatment in preventing recurrent febrile seizures, it had no positive effect on patient outcome or risk of developing epilepsy. The treatment of simple febrile seizures with anticonvulsant prophylaxis is no longer recommended.

## Society and culture

### Names

Phenobarbital is the International Nonproprietary Name (INN) and phenobarbitone is the British Approved Name (BAN).

### Synthesis

Barbiturate drugs are obtained via condensation reactions between a derivative of diethyl malonate and urea in the presence of a strong base. The synthesis of phenobarbital uses this common approach as well but differs in the way in which this malonate derivative is obtained. The reason for this difference is because aryl halides do not typically undergo nucleophilic substitution in Malonic ester synthesis in the same way as aliphatic organosulfates or halocarbons do. To overcome this lack of chemical reactivity two dominant synthetic approaches using benzyl cyanide as a starting material have been developed:
The first of these methods consists of a Pinner reaction of benzyl cyanide, giving phenylacetic acid ethyl ester. Subsequently, this ester undergoes cross Claisen condensation using diethyl oxalate, giving diethyl ester of phenyloxobutandioic acid. Upon heating this intermediate easily loses carbon monoxide, yielding diethyl phenylmalonate. Malonic ester synthesis using ethyl bromide leads to the formation of α-phenyl-α-ethylmalonic ester. Finally, a condensation reaction with urea gives phenobarbital.

The second approach utilizes diethyl carbonate in the presence of a strong base to give α-phenylcyanoacetic ester. Alkylation of this ester using ethyl bromide proceeds via a nitrile anion intermediate to give the α-phenyl-α-ethylcyanoacetic ester. This product is then further converted into the 4-iminoderivative upon condensation with urea. Finally acidic hydrolysis of the resulting product gives phenobarbital.

A new synthetic route based on diethyl 2-ethyl-2-phenylmalonate and urea has been described.

### Regulation

The level of regulation includes Schedule IV non-narcotic (depressant) (ACSCN 2285) in the United States under the Controlled Substances Act 1970—but along with a few other barbiturates and at least one benzodiazepine, and codeine, dionine, or dihydrocodeine at low concentrations, it also has exempt prescription and had at least one exempt OTC combination drug now more tightly regulated for its ephedrine content. The phenobarbitone/phenobarbital exists in subtherapeutic doses which add up to an effective dose to counter the overstimulation and possible seizures from a deliberate overdose in ephedrine tablets for asthma, which are now regulated at the federal and state level as: a restricted OTC medicine and/or watched precursor, uncontrolled but watched/restricted prescription drug & watched precursor, a Schedule II, III, IV, or V prescription-only controlled substance & watched precursor, or a Schedule V (which also has possible regulations at the county/parish, town, city, or district as well aside from the fact that the pharmacist can also choose not to sell it, and photo ID and signing a register is required) exempt Non-Narcotic restricted/watched OTC medicine.

### Selected overdoses

A mysterious woman, known as the Isdal Woman, was found dead in Bergen, Norway, on 29 November 1970. Her death was caused by some combination of burns, phenobarbital, and carbon monoxide poisoning; many theories about her death have been posited, and it is believed that she may have been a spy.
British veterinarian Donald Sinclair, better known as the character Siegfried Farnon in the "All Creatures Great and Small" book series by James Herriot, committed suicide at the age of 84 by injecting himself with an overdose of phenobarbital. Activist Abbie Hoffman also committed suicide by consuming phenobarbital, combined with alcohol, on 12 April 1989; the residue of around 150 pills was found in his body at autopsy.
Thirty-nine members of the Heaven's Gate UFO cult committed mass suicide in March 1997 by drinking a lethal dose of phenobarbital and vodka "and then lay down to die" hoping to enter an alien spacecraft.

## Veterinary uses

Phenobarbital is one of the first-line drugs of choice to treat epilepsy in dogs, as well as cats.
It is also used to treat feline hyperesthesia syndrome in cats when anti-obsessional therapies prove ineffective.
It may also be used to treat seizures in horses when benzodiazepine treatment has failed or is contraindicated.

== References ==
`,
};
